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The novel severe-acute respiratory coronavirus 2 (SARS-CoV-2) 
is the cause of COVID-19, a condition that was declared a global 
pandemic by the World Health Organization on 30 January 2020. As 
of 20 August, a total of 213 countries and territories were affected 
by the pandemic, with >22 256 219 confirmed cases globally.[1] The 
prognosis of the disease in patients with underlying conditions is 
dire, with comorbidities reported in a large number of hospitalised 
and severe cases.[2] Based on initial reports, older individuals and 
individuals with pre-existing conditions such as diabetes, heart 
disease, chronic obstructive pulmonary disease and cancer are 
more predisposed than others to severe COVID-19.[2,3] While 
the mechanistic links between the aforementioned pre-existing 
conditions and COVID-19 severity are being unravelled, reasons 
for severe COVID-19 in individuals without a known history of 
comorbidities (otherwise healthy individuals) are somewhat puzzling 
and may be compounded by genetics, such as the ABO blood group, 
and androgens, which may predispose a person to adverse COVID-
19 outcomes.[4-6] While there is much we have yet to learn about the 
disease, it is therefore clear that an immunocompromising condition 
places the patient at a disadvantage against SARS-CoV-2.
The high incidence of severe infection and mortality in COVID-19 
is thought to be due in part to a lack of natural immunity and to viral 
replication in the lower respiratory tract, as well as superinfections, 
secondary infections or co-infections (these terms are often used 
interchangeably), leading to severe lung injury and acute respiratory 
distress syndrome (ARDS).[7] Co-infections with respiratory viruses 
(other than SARS-CoV-2), bacteria and fungi have been reported in 
COVID-19 patients in Wuhan, China,[8-10] and secondary infections 
were identified as one of the predictors of a fatal outcome in COVID-
19 cases.[11] An earlier report from China suggests that the mortality 
rate for COVID-19 patients on ventilators in intensive care units 
(ICUs) is ~60%, and indicated that invasive fungal co-infections may 
contribute to this high mortality.[2]
Invasive fungal infections, including aspergillosis and candi-
diasis,[12-14] are prevalent in hospitalised patients, and it is commonly 
established that acute respiratory disease, including invasive 
pulmonary aspergillosis (IPA), is frequent in ICUs and among 
immunocompromised populations.[15-18] In addition, in some patients 
without a well-defined underlying immunocompromising disease, 
there is a high risk of secondary complications with IPA in ARDS 
due to viral infection.[19-22] However, few such co-infections are being 
reported in the current COVID-19 pandemic, especially in South 
Africa (SA).
Fungal co-infections are prevalent in 
critically ill COVID-19 patients: Are 
they risk factors for severe outcomes?
Fungal infections, either pre or post COVID-19 exposure, can 
complicate diagnosis, treatment and progression of COVID-19.[10,23-25] 
At this stage, data on pre-existing fungal infections are mostly not 
reported. This is in part due to the likelihood of undiagnosed fungal 
infections in healthy individuals pre COVID-19 exposure, a lack 
of comprehensive descriptions of patients’ clinical characteristics, 
and prioritisation of COVID-19 diagnosis over fungal infection 
diagnosis.[24,26-28] However, a retrospective study by Gao et al.[29] in 
China showed that the presence of a coexisting medical condition 
was the only independent risk factor for the ARDS in influenza A 
(H7N9) patients during the spring of 2013, with secondary bacterial 
or fungal infection being the cause of death in 3 out of 30 patients 
(10%) who died. Shortly before the outbreak of SARS-CoV-2, Gao 
et al.[29] showed that 25 of 528 patients (4.8%) with viral pneumonia 
had fungal co-infections. Of these patients, 12 survived while 13 
died. [29] In addition, data from previous coronavirus outbreaks (SARS 
(severe acute respiratory syndrome)-CoV and MERS (Middle East 
respiratory syndrome)) have indicated that invasive aspergillosis and 
other systemic fungal infections contributed to severe outcomes for 
patients in ICUs.[19,30,31]
With regard to secondary infections or co-infection, data 
from several countries show prevalence of fungal co-infections 
in COVID-19 patients (Table 1). From these data, it is evident 
that the majority of these infections are caused by Aspergillus 
(mostly A. fumigatus) and Candida species. These infections are not 
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COVID-19 exclusive, but are often observed in patients admitted 
to ICUs.[32] This finding complicates establishment of a causal 
relationship between fungal co-infection and COVID-19 disease 
severity, as there may be underlying conditions that predispose a 
patient to both infections. Interestingly, Zuo et al.[33] reported that the 
gastrointestinal mycobiomes of hospitalised COVID-19 patients were 
more heterogeneous, more enriched for C. albicans and contained 
higher levels of C. auris and A. flavus compared with controls, even 
after resolution of symptoms. This finding highlights the question 
whether fungal colonisation contributes to or results from SARS-
CoV-2 infection.
An SA perspective
Studies conducted before the current COVID-19 pandemic showed 
that fungal infections are highly prevalent in the SA population, 
partly owing to the high incidence of HIV.[34-36] It was observed that 
the Candida carrier rate is higher in the SA population than elsewhere 
and that HIV-positive patients carry more and a greater variety 
of pathogenic yeasts compared with HIV-negative subjects. [35,36] 
Similarly, cryptococcal meningitis, caused by Cryptococcus neoformans 
species complex, is one of the leading causes of HIV-related deaths 
in SA, with >135 900 deaths estimated for sub-Saharan Africa in 
2014.[34,35,37] Other fungal infections, including invasive aspergillosis, 
Pneumocystis pneumonia and endemic mycoses, are also prevalent in 
SA.[34] Given the high prevalence of HIV/AIDS in SA as well as the 
high number of persons undergoing immunosuppressive therapies 
for other illnesses, co-infections with opportunistic fungal species 
may be affecting the current COVID-19 disease statistics in SA. 
Unfortunately, information on microbial co-infections in COVID-
19 patients is lacking in currently published epidemiological and 
clinical reports on COVID-19 patients in SA.[38,39] The extent and 
contribution of such fungal co-infections (either pre-existing or 
nosocomial) on COVID-19 patient outcomes in SA are therefore 
unclear. In time, meta-analyses of case reports from COVID-19 
patients may help provide such answers. However, this requires that 
patients’ histories, disease characteristics and prognosis must be well 
documented and accessible for meta-analyses, both globally and 
in SA. Such information is vital for the full appreciation of factors 
contributing to the current COVID-19 statistics in SA.
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